Compare ELWS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELWS | NXL |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 18.6M |
| IPO Year | 2023 | 2022 |
| Metric | ELWS | NXL |
|---|---|---|
| Price | $7.10 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 26.6K | ★ 177.0K |
| Earning Date | 03-02-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,083,071.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 145.52 | N/A |
| 52 Week Low | $1.64 | $0.54 |
| 52 Week High | $10.50 | $3.87 |
| Indicator | ELWS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 36.27 |
| Support Level | $5.40 | $0.61 |
| Resistance Level | $6.34 | $0.77 |
| Average True Range (ATR) | 0.81 | 0.06 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 90.00 | 2.06 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.